William G. Wright

Array ( [id] => 17050759 [patent_doc_number] => 20210260193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM [patent_app_type] => utility [patent_app_number] => 17/318691 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23889 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065746 [patent_doc_number] => 20210267961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => METHOD OF TREATING LAMINOPATHIES [patent_app_type] => utility [patent_app_number] => 17/317170 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18793880 [patent_doc_number] => 11827632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-28 [patent_title] => NLRP3 modulators [patent_app_type] => utility [patent_app_number] => 17/313319 [patent_app_country] => US [patent_app_date] => 2021-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35297 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17034994 [patent_doc_number] => 20210251952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/308910 [patent_app_country] => US [patent_app_date] => 2021-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13052 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052074 [patent_doc_number] => 20210261508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => METHODS FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS [patent_app_type] => utility [patent_app_number] => 17/229593 [patent_app_country] => US [patent_app_date] => 2021-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17229593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140140 [patent_doc_number] => 20210308151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => ACTIVATING ENDOGENOUS ANTIMICROBIALS TO TREAT SARS-COV-2 INFECTION [patent_app_type] => utility [patent_app_number] => 17/223631 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17223631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541683 [patent_doc_number] => 20240358719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation [patent_app_type] => utility [patent_app_number] => 18/553474 [patent_app_country] => US [patent_app_date] => 2021-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -82 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449464 [patent_doc_number] => 20230190740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => AN NK-1 RECEPTOR ANTAGONIST FOR TREATING A DISEASE SELECTING FROM SEPSIS, SEPTIC SHOCK, ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) OR MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS) [patent_app_type] => utility [patent_app_number] => 17/907291 [patent_app_country] => US [patent_app_date] => 2021-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16961468 [patent_doc_number] => 20210212967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => Treatment of Irritable Bowel Syndrome [patent_app_type] => utility [patent_app_number] => 17/215050 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17215050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18326014 [patent_doc_number] => 20230124142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => NEW THERAPEUTIC TARGETS WITH AN ANTI-INFLAMMATORY AND ANTI-INTERFERON EFFECT [patent_app_type] => utility [patent_app_number] => 17/907305 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842674 [patent_doc_number] => 20230405078 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => DETECTION AND TREATMENT OF INTESTINAL FIBROSIS [patent_app_type] => utility [patent_app_number] => 17/907220 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420122 [patent_doc_number] => 20230174583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => PREPARATION OF CYCLOSPORIN DERIVATIVES [patent_app_type] => utility [patent_app_number] => 17/906348 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18339980 [patent_doc_number] => 20230131929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 17/914146 [patent_app_country] => US [patent_app_date] => 2021-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18575492 [patent_doc_number] => 11732006 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => IBAT inhibitors for the treatment of liver diseases [patent_app_type] => utility [patent_app_number] => 17/206925 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14314 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420163 [patent_doc_number] => 20230174624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => FERRITIN VARIANTS WITH INCREASED STABILITY, COMPLEXATION ABILITY AND TRANSFERRIN RECEPTOR AFFINITY [patent_app_type] => utility [patent_app_number] => 17/906092 [patent_app_country] => US [patent_app_date] => 2021-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18312376 [patent_doc_number] => 20230116276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS [patent_app_type] => utility [patent_app_number] => 17/906186 [patent_app_country] => US [patent_app_date] => 2021-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418419 [patent_doc_number] => 20230172877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => METABOLITES RELEASED FROM APOPTOTIC CELLS ACT AS NOVEL TISSUE MESSENGERS [patent_app_type] => utility [patent_app_number] => 17/910613 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18346733 [patent_doc_number] => 20230134843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => TREATMENT OF STEM CELL DEFICIENCY [patent_app_type] => utility [patent_app_number] => 17/910971 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18700038 [patent_doc_number] => 11786524 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Pharmaceutical compounds [patent_app_type] => utility [patent_app_number] => 17/191151 [patent_app_country] => US [patent_app_date] => 2021-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50030 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1045 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17191151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16898918 [patent_doc_number] => 20210177834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION [patent_app_type] => utility [patent_app_number] => 17/187454 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187454 [rel_patent_id] =>[rel_patent_doc_number] =>)